Videos | Radial Access | March 22, 2011

VIDEO: Tour of a Radial Access Recovery Lounge That Mimics Cafe Atmosphere

St. Joseph's Hospital of Atlanta created a radial access recover room that replaces beds and the sterile institutional hospital look with a more patient-friendly design. Transradial access is slowly gaining ground in the United States as more physicians make the switch due to greatly reduced bleeding complications, increased patient comfort and earlier ambulation. St. Joseph's Hospital of Atlanta is a big supporter of radial access and has taken the concept a step further by creating the first transradial recovery lounge in the country.

"I really see this as the future of cardiac care, not just as an alternative access route for percutaneous coronary intervention, but also to improve the patient experience and reduce their hospital stay," said Jack P. Chen, M.D., FACC, FSCAI, FCCP, director of cardiac research, St. Joseph's Translational Research Institute, Saint Joseph's Heart and Vascular Institute, Atlanta. A trend in medical facility design over the past 15 years has moved away from the sterile, institutional look of traditional hospitals. Instead, more inviting, warm and friendly looking facilities are being built to make patients feel more comfortable. This concept is now being applied to the cath lab recovery room. Use of radial access allows for immediate ambulation, and thus a major revision to recovery room design, replacing beds with couches and recliner chairs. St. Joseph's Hospital is the first in the United States to build a cafe-like lounge exclusively for radial access patients.

Chen took the idea from Ferdinand Kiemeneij, M.D., department of interventional cardiology, Onze Lieve Vrouwe Gasthuis, Amsterdam, The Netherlands. He created the first radial access recovery room in Europe after getting the idea from a KLM airline lounge. "The idea is to build a cafe-type atmosphere to reduce the anxiety associated with invasive heart procedures," Chen said. "When I first approached the hospital administration with this idea, they required a bit of convincing. However, after seeing the patient satisfaction and alleviation of complications stemming from this technique, all were in agreement that this concept may well be the wave of the future."

Watch a VIDEO interview with Kiemeneij on the history of radial access. 

He said the hospital embraces the radial access approach as a new frontier in interventional cardiology and agreed to build the new recovery area. "To me, this rounded out the picture of a more patient-friendly cardiology program for what is essentially a minimally invasive catheterization/interventional procedure," Chen said. Patients sit in the lounge chairs for 30 minutes to an hour, only to recover from the sedation. The patients are then allowed to ambulate in their street clothes. They can walk around or sip a cappuccino, Chen said.

The recovery room has comfortable reclining chairs instead of beds and there are couches and coffee tables topped with magazines and newspapers. The recliners have attached swing-up tabletops where patients can put a laptop computer and check their e-mail or surf the Internet. The idea is to eliminate the sterile, institutional appearance of most recovery rooms and to relax the patient with a more inviting atmosphere. â??We are trying to take the hospital out of the equation," Chen said. "Patients are much more at ease than they would be in a typical hospital setting. To allow them to put their street clothes on really reduces the anxiety they have." The lounge was showcased and visited by many cardiologists from around the country during the American College of Cardiology (ACC) Annual Scientific Sessions in March 2010, which were held in Atlanta.

3152 Views

Recent Videos View all 619 items

Cardiovascular Ultrasound | November 24, 2021

Examples of TrueView and GlassView 3D cardiac ultrasound visualization and artificial intelligence (AI) assisted automated measurements on the Philips Healthcare Epiq CV version 9.0 echo system. The latest version of the system was FDA cleared in October 2021 and shown at the 2021 Radiological Society of North America (RSNA) meeting for the first time. The Epiq is an AI-based platform, starting with anatomical intelligence to identify the anatomy being images automatically. The latest version of the system adds additional AI auto measurements and quantification to save time, speed workflow and reduce intra-operator variability. 

The short video shows photo-realistic rendering of the mitral valve and a new feature where the opacity of the tissue can be dialed in our out to show glass-like ghost view of the tissue. This can make it easier to navigate or see anatomical landmarks without rotating or slicing through the image planes in the 3D rendering.

Find more RSNA news and video

Find more cardiac echo technology news
 

EP Lab | November 22, 2021

Christine Albert, M.D., MPH, professor, chair of the Department of Cardiology and the Lee and Harold Kapelovitz Distinguished Chair in Cardiology, and former president of the Heart Rhythm Society (HRS). She spoke at the American Heart Association (AHA) 2021 meeting on innovations in electrophysiology (EP) technologies. 

Advances she discusses include:
   • Leadless pacing and CRT systems  
   • Wearable patch heart monitors and that are largely replacing traditional Holter monitors.
   • Pulsed field ablation (also called electroporation) that may improve cardiac ablations and prevent damage to underlying tissues.
   • Cryo-ablation balloons.
   • Improved EP mapping technologies.
   • and left atrial appendage (LAA) occluders.

Find more EP lab technology news

Find More AHA 2021 Late-breaking News

Genetic Testing | November 22, 2021

Susan Cheng, M.D., MPH, director of the Institute for Research on Healthy Aging in the Department of Cardiology at Cedars-Sinai, moderated the Best Science in Cardiovascular Genetics and Genomics: Building Blocks to Better Outcomes, at the American Heart Association (AHA) 2021 meeting. She is an expert in cardiac genetic testing and said tailoring LDL-lowering drug therapy based on routine genetic tests is coming, but is still a few years off.

Find more AHA 2021 late-breaking studies and video

Pharmaceuticals | November 22, 2021

Susan Cheng, M.D., MPH, director of the Institute for Research on Healthy Aging in the Department of Cardiology at Cedars-Sinai and the Erika J. Glazer Chair in Women's Cardiovascular Health and Population Science, led a discussion at the American Heart Association (AHA) 2021 meeting on novel therapeutics for the lipid lowering treatments. 

She discusses bempedoic acid, inclisiran to reduce LDL-C, icosapent ethyl and the use of genetic testing to further reduce high low-density lipoprotein (LDL) in patients were statin therapy is not enough.

Cheng discusses more in the VIDEO: Use of Genetic Testing to Tailor Lipid Lowering Therapies.

Find more AHA 2021 late-breaking studies and video

 

Sponsored Videos View all 41 items

Information Technology | April 17, 2019

With Intellispace Enterprise Edition as the foundation, Philips Healthcare is connecting facilities and service areas within enterprises, while developing standards-based interoperability that preserves customers' investments and best of breed systems. 

Hemodynamic Support Devices | March 06, 2019

Perwaiz Meraj, M.D., FACC, FSCAI, director of interventional cardiology, assistant professor, Donald and Barbara Zucker School of Medicine at Hofstra/Northwell, Northwell Health System discusses the importance of hemodynamic support to safely perform a percutaneous coronary intervention (PCI) with prior coronary artery bypass graft (CABG) surgery and comorbidities. Learn more at ProtectedPCI.com/DAIC.

In this video, Meraj discuss a complex coronary intervention of a 77-year-old woman with stage 4 CKD, prior CABG, hypertension, hyperlipidemia, diabetes, who presented with angina and NSTEMI with an ejection fraction of 40 percent. The team at Northwell consulted with cardiac surgeons and the heart team, and determined that this patient was too high risk for another bypass surgery. Read more on this case.
 

Related Impella Video Content:

VIDEO: Analysis of Outcomes for 15,259 U.S. Patients with AMICS Supported with the Impella Device — Interview with William O'Neill, M.D.

VIDEO: The Door-to-Unloading (DTU) STEMI Safety and Feasibility Trial — Interview with Navin Kapur, M.D.

VIDEO: Cardiogenic Shock Case with Impella CP Support — Case study with Michael Amponsah, M.D.,

 

 

Heart Failure | February 13, 2019

William O'Neill, M.D., highlights best practice protocols based on Impella Quality database and real-world evidence showing improved outcomes in cardiogenic shock. Learn more at ProtectedPCI.com/DAIC

 

Related Impella Video Content:

VIDEO: Complex PCI Involving Prior CABG and Comorbidities — Interview with Perwaiz Meraj, M.D.

VIDEO: The Door-to-Unloading (DTU) STEMI Safety and Feasibility Trial — Interview with Navin Kapur, M.D.

VIDEO: Cardiogenic Shock Case with Impella CP Support — Case study with Michael Amponsah, M.D.,

 

January 10, 2019

Mark Anderson, M.D., FACS, vice chair of cardiac surgery services and cardiothoracic surgeon at Hackensack University Medical Group, outlines a multi-disciplinary heart team approach in treament decision-making for patients in cardiogenic shock. Learn more at ProtectedPCI.com/DAIC.

Anderson discusses improving outcomes for patients in cardiogenic shock through the early use of mechanical circulatory support and the development of a shock protocol with the heart team. He outlines Hackensack University Medical Center’s multi-disciplinary, heart team approach in treatment decision-making for patients in cardiogenic shock. The team includes cardiac surgeons, interventional cardiologists, heart failure specialists and intensivists. 

 

 

Conference Coverage View all 449 items

Cardiovascular Ultrasound | November 24, 2021

Examples of TrueView and GlassView 3D cardiac ultrasound visualization and artificial intelligence (AI) assisted automated measurements on the Philips Healthcare Epiq CV version 9.0 echo system. The latest version of the system was FDA cleared in October 2021 and shown at the 2021 Radiological Society of North America (RSNA) meeting for the first time. The Epiq is an AI-based platform, starting with anatomical intelligence to identify the anatomy being images automatically. The latest version of the system adds additional AI auto measurements and quantification to save time, speed workflow and reduce intra-operator variability. 

The short video shows photo-realistic rendering of the mitral valve and a new feature where the opacity of the tissue can be dialed in our out to show glass-like ghost view of the tissue. This can make it easier to navigate or see anatomical landmarks without rotating or slicing through the image planes in the 3D rendering.

Find more RSNA news and video

Find more cardiac echo technology news
 

EP Lab | November 22, 2021

Christine Albert, M.D., MPH, professor, chair of the Department of Cardiology and the Lee and Harold Kapelovitz Distinguished Chair in Cardiology, and former president of the Heart Rhythm Society (HRS). She spoke at the American Heart Association (AHA) 2021 meeting on innovations in electrophysiology (EP) technologies. 

Advances she discusses include:
   • Leadless pacing and CRT systems  
   • Wearable patch heart monitors and that are largely replacing traditional Holter monitors.
   • Pulsed field ablation (also called electroporation) that may improve cardiac ablations and prevent damage to underlying tissues.
   • Cryo-ablation balloons.
   • Improved EP mapping technologies.
   • and left atrial appendage (LAA) occluders.

Find more EP lab technology news

Find More AHA 2021 Late-breaking News

Genetic Testing | November 22, 2021

Susan Cheng, M.D., MPH, director of the Institute for Research on Healthy Aging in the Department of Cardiology at Cedars-Sinai, moderated the Best Science in Cardiovascular Genetics and Genomics: Building Blocks to Better Outcomes, at the American Heart Association (AHA) 2021 meeting. She is an expert in cardiac genetic testing and said tailoring LDL-lowering drug therapy based on routine genetic tests is coming, but is still a few years off.

Find more AHA 2021 late-breaking studies and video

Pharmaceuticals | November 22, 2021

Susan Cheng, M.D., MPH, director of the Institute for Research on Healthy Aging in the Department of Cardiology at Cedars-Sinai and the Erika J. Glazer Chair in Women's Cardiovascular Health and Population Science, led a discussion at the American Heart Association (AHA) 2021 meeting on novel therapeutics for the lipid lowering treatments. 

She discusses bempedoic acid, inclisiran to reduce LDL-C, icosapent ethyl and the use of genetic testing to further reduce high low-density lipoprotein (LDL) in patients were statin therapy is not enough.

Cheng discusses more in the VIDEO: Use of Genetic Testing to Tailor Lipid Lowering Therapies.

Find more AHA 2021 late-breaking studies and video

 

Cath Lab View all 311 items

Cardiovascular Ultrasound | November 24, 2021

Examples of TrueView and GlassView 3D cardiac ultrasound visualization and artificial intelligence (AI) assisted automated measurements on the Philips Healthcare Epiq CV version 9.0 echo system. The latest version of the system was FDA cleared in October 2021 and shown at the 2021 Radiological Society of North America (RSNA) meeting for the first time. The Epiq is an AI-based platform, starting with anatomical intelligence to identify the anatomy being images automatically. The latest version of the system adds additional AI auto measurements and quantification to save time, speed workflow and reduce intra-operator variability. 

The short video shows photo-realistic rendering of the mitral valve and a new feature where the opacity of the tissue can be dialed in our out to show glass-like ghost view of the tissue. This can make it easier to navigate or see anatomical landmarks without rotating or slicing through the image planes in the 3D rendering.

Find more RSNA news and video

Find more cardiac echo technology news
 

EP Lab | November 22, 2021

Christine Albert, M.D., MPH, professor, chair of the Department of Cardiology and the Lee and Harold Kapelovitz Distinguished Chair in Cardiology, and former president of the Heart Rhythm Society (HRS). She spoke at the American Heart Association (AHA) 2021 meeting on innovations in electrophysiology (EP) technologies. 

Advances she discusses include:
   • Leadless pacing and CRT systems  
   • Wearable patch heart monitors and that are largely replacing traditional Holter monitors.
   • Pulsed field ablation (also called electroporation) that may improve cardiac ablations and prevent damage to underlying tissues.
   • Cryo-ablation balloons.
   • Improved EP mapping technologies.
   • and left atrial appendage (LAA) occluders.

Find more EP lab technology news

Find More AHA 2021 Late-breaking News

Genetic Testing | November 22, 2021

Susan Cheng, M.D., MPH, director of the Institute for Research on Healthy Aging in the Department of Cardiology at Cedars-Sinai, moderated the Best Science in Cardiovascular Genetics and Genomics: Building Blocks to Better Outcomes, at the American Heart Association (AHA) 2021 meeting. She is an expert in cardiac genetic testing and said tailoring LDL-lowering drug therapy based on routine genetic tests is coming, but is still a few years off.

Find more AHA 2021 late-breaking studies and video

Pharmaceuticals | November 22, 2021

Susan Cheng, M.D., MPH, director of the Institute for Research on Healthy Aging in the Department of Cardiology at Cedars-Sinai and the Erika J. Glazer Chair in Women's Cardiovascular Health and Population Science, led a discussion at the American Heart Association (AHA) 2021 meeting on novel therapeutics for the lipid lowering treatments. 

She discusses bempedoic acid, inclisiran to reduce LDL-C, icosapent ethyl and the use of genetic testing to further reduce high low-density lipoprotein (LDL) in patients were statin therapy is not enough.

Cheng discusses more in the VIDEO: Use of Genetic Testing to Tailor Lipid Lowering Therapies.

Find more AHA 2021 late-breaking studies and video

 

Cardiac Imaging View all 271 items

Cardiovascular Ultrasound | November 24, 2021

Examples of TrueView and GlassView 3D cardiac ultrasound visualization and artificial intelligence (AI) assisted automated measurements on the Philips Healthcare Epiq CV version 9.0 echo system. The latest version of the system was FDA cleared in October 2021 and shown at the 2021 Radiological Society of North America (RSNA) meeting for the first time. The Epiq is an AI-based platform, starting with anatomical intelligence to identify the anatomy being images automatically. The latest version of the system adds additional AI auto measurements and quantification to save time, speed workflow and reduce intra-operator variability. 

The short video shows photo-realistic rendering of the mitral valve and a new feature where the opacity of the tissue can be dialed in our out to show glass-like ghost view of the tissue. This can make it easier to navigate or see anatomical landmarks without rotating or slicing through the image planes in the 3D rendering.

Find more RSNA news and video

Find more cardiac echo technology news
 

EP Lab | November 22, 2021

Christine Albert, M.D., MPH, professor, chair of the Department of Cardiology and the Lee and Harold Kapelovitz Distinguished Chair in Cardiology, and former president of the Heart Rhythm Society (HRS). She spoke at the American Heart Association (AHA) 2021 meeting on innovations in electrophysiology (EP) technologies. 

Advances she discusses include:
   • Leadless pacing and CRT systems  
   • Wearable patch heart monitors and that are largely replacing traditional Holter monitors.
   • Pulsed field ablation (also called electroporation) that may improve cardiac ablations and prevent damage to underlying tissues.
   • Cryo-ablation balloons.
   • Improved EP mapping technologies.
   • and left atrial appendage (LAA) occluders.

Find more EP lab technology news

Find More AHA 2021 Late-breaking News

Genetic Testing | November 22, 2021

Susan Cheng, M.D., MPH, director of the Institute for Research on Healthy Aging in the Department of Cardiology at Cedars-Sinai, moderated the Best Science in Cardiovascular Genetics and Genomics: Building Blocks to Better Outcomes, at the American Heart Association (AHA) 2021 meeting. She is an expert in cardiac genetic testing and said tailoring LDL-lowering drug therapy based on routine genetic tests is coming, but is still a few years off.

Find more AHA 2021 late-breaking studies and video

Pharmaceuticals | November 22, 2021

Susan Cheng, M.D., MPH, director of the Institute for Research on Healthy Aging in the Department of Cardiology at Cedars-Sinai and the Erika J. Glazer Chair in Women's Cardiovascular Health and Population Science, led a discussion at the American Heart Association (AHA) 2021 meeting on novel therapeutics for the lipid lowering treatments. 

She discusses bempedoic acid, inclisiran to reduce LDL-C, icosapent ethyl and the use of genetic testing to further reduce high low-density lipoprotein (LDL) in patients were statin therapy is not enough.

Cheng discusses more in the VIDEO: Use of Genetic Testing to Tailor Lipid Lowering Therapies.

Find more AHA 2021 late-breaking studies and video

 

Cardiac Diagnostics View all 74 items

Cardiovascular Ultrasound | November 24, 2021

Examples of TrueView and GlassView 3D cardiac ultrasound visualization and artificial intelligence (AI) assisted automated measurements on the Philips Healthcare Epiq CV version 9.0 echo system. The latest version of the system was FDA cleared in October 2021 and shown at the 2021 Radiological Society of North America (RSNA) meeting for the first time. The Epiq is an AI-based platform, starting with anatomical intelligence to identify the anatomy being images automatically. The latest version of the system adds additional AI auto measurements and quantification to save time, speed workflow and reduce intra-operator variability. 

The short video shows photo-realistic rendering of the mitral valve and a new feature where the opacity of the tissue can be dialed in our out to show glass-like ghost view of the tissue. This can make it easier to navigate or see anatomical landmarks without rotating or slicing through the image planes in the 3D rendering.

Find more RSNA news and video

Find more cardiac echo technology news
 

EP Lab | November 22, 2021

Christine Albert, M.D., MPH, professor, chair of the Department of Cardiology and the Lee and Harold Kapelovitz Distinguished Chair in Cardiology, and former president of the Heart Rhythm Society (HRS). She spoke at the American Heart Association (AHA) 2021 meeting on innovations in electrophysiology (EP) technologies. 

Advances she discusses include:
   • Leadless pacing and CRT systems  
   • Wearable patch heart monitors and that are largely replacing traditional Holter monitors.
   • Pulsed field ablation (also called electroporation) that may improve cardiac ablations and prevent damage to underlying tissues.
   • Cryo-ablation balloons.
   • Improved EP mapping technologies.
   • and left atrial appendage (LAA) occluders.

Find more EP lab technology news

Find More AHA 2021 Late-breaking News

Genetic Testing | November 22, 2021

Susan Cheng, M.D., MPH, director of the Institute for Research on Healthy Aging in the Department of Cardiology at Cedars-Sinai, moderated the Best Science in Cardiovascular Genetics and Genomics: Building Blocks to Better Outcomes, at the American Heart Association (AHA) 2021 meeting. She is an expert in cardiac genetic testing and said tailoring LDL-lowering drug therapy based on routine genetic tests is coming, but is still a few years off.

Find more AHA 2021 late-breaking studies and video

Pharmaceuticals | November 22, 2021

Susan Cheng, M.D., MPH, director of the Institute for Research on Healthy Aging in the Department of Cardiology at Cedars-Sinai and the Erika J. Glazer Chair in Women's Cardiovascular Health and Population Science, led a discussion at the American Heart Association (AHA) 2021 meeting on novel therapeutics for the lipid lowering treatments. 

She discusses bempedoic acid, inclisiran to reduce LDL-C, icosapent ethyl and the use of genetic testing to further reduce high low-density lipoprotein (LDL) in patients were statin therapy is not enough.

Cheng discusses more in the VIDEO: Use of Genetic Testing to Tailor Lipid Lowering Therapies.

Find more AHA 2021 late-breaking studies and video

 

EP Lab View all 82 items

Cardiovascular Ultrasound | November 24, 2021

Examples of TrueView and GlassView 3D cardiac ultrasound visualization and artificial intelligence (AI) assisted automated measurements on the Philips Healthcare Epiq CV version 9.0 echo system. The latest version of the system was FDA cleared in October 2021 and shown at the 2021 Radiological Society of North America (RSNA) meeting for the first time. The Epiq is an AI-based platform, starting with anatomical intelligence to identify the anatomy being images automatically. The latest version of the system adds additional AI auto measurements and quantification to save time, speed workflow and reduce intra-operator variability. 

The short video shows photo-realistic rendering of the mitral valve and a new feature where the opacity of the tissue can be dialed in our out to show glass-like ghost view of the tissue. This can make it easier to navigate or see anatomical landmarks without rotating or slicing through the image planes in the 3D rendering.

Find more RSNA news and video

Find more cardiac echo technology news
 

EP Lab | November 22, 2021

Christine Albert, M.D., MPH, professor, chair of the Department of Cardiology and the Lee and Harold Kapelovitz Distinguished Chair in Cardiology, and former president of the Heart Rhythm Society (HRS). She spoke at the American Heart Association (AHA) 2021 meeting on innovations in electrophysiology (EP) technologies. 

Advances she discusses include:
   • Leadless pacing and CRT systems  
   • Wearable patch heart monitors and that are largely replacing traditional Holter monitors.
   • Pulsed field ablation (also called electroporation) that may improve cardiac ablations and prevent damage to underlying tissues.
   • Cryo-ablation balloons.
   • Improved EP mapping technologies.
   • and left atrial appendage (LAA) occluders.

Find more EP lab technology news

Find More AHA 2021 Late-breaking News

Genetic Testing | November 22, 2021

Susan Cheng, M.D., MPH, director of the Institute for Research on Healthy Aging in the Department of Cardiology at Cedars-Sinai, moderated the Best Science in Cardiovascular Genetics and Genomics: Building Blocks to Better Outcomes, at the American Heart Association (AHA) 2021 meeting. She is an expert in cardiac genetic testing and said tailoring LDL-lowering drug therapy based on routine genetic tests is coming, but is still a few years off.

Find more AHA 2021 late-breaking studies and video

Pharmaceuticals | November 22, 2021

Susan Cheng, M.D., MPH, director of the Institute for Research on Healthy Aging in the Department of Cardiology at Cedars-Sinai and the Erika J. Glazer Chair in Women's Cardiovascular Health and Population Science, led a discussion at the American Heart Association (AHA) 2021 meeting on novel therapeutics for the lipid lowering treatments. 

She discusses bempedoic acid, inclisiran to reduce LDL-C, icosapent ethyl and the use of genetic testing to further reduce high low-density lipoprotein (LDL) in patients were statin therapy is not enough.

Cheng discusses more in the VIDEO: Use of Genetic Testing to Tailor Lipid Lowering Therapies.

Find more AHA 2021 late-breaking studies and video

 

Information Technology View all 164 items

Cardiovascular Ultrasound | November 24, 2021

Examples of TrueView and GlassView 3D cardiac ultrasound visualization and artificial intelligence (AI) assisted automated measurements on the Philips Healthcare Epiq CV version 9.0 echo system. The latest version of the system was FDA cleared in October 2021 and shown at the 2021 Radiological Society of North America (RSNA) meeting for the first time. The Epiq is an AI-based platform, starting with anatomical intelligence to identify the anatomy being images automatically. The latest version of the system adds additional AI auto measurements and quantification to save time, speed workflow and reduce intra-operator variability. 

The short video shows photo-realistic rendering of the mitral valve and a new feature where the opacity of the tissue can be dialed in our out to show glass-like ghost view of the tissue. This can make it easier to navigate or see anatomical landmarks without rotating or slicing through the image planes in the 3D rendering.

Find more RSNA news and video

Find more cardiac echo technology news
 

EP Lab | November 22, 2021

Christine Albert, M.D., MPH, professor, chair of the Department of Cardiology and the Lee and Harold Kapelovitz Distinguished Chair in Cardiology, and former president of the Heart Rhythm Society (HRS). She spoke at the American Heart Association (AHA) 2021 meeting on innovations in electrophysiology (EP) technologies. 

Advances she discusses include:
   • Leadless pacing and CRT systems  
   • Wearable patch heart monitors and that are largely replacing traditional Holter monitors.
   • Pulsed field ablation (also called electroporation) that may improve cardiac ablations and prevent damage to underlying tissues.
   • Cryo-ablation balloons.
   • Improved EP mapping technologies.
   • and left atrial appendage (LAA) occluders.

Find more EP lab technology news

Find More AHA 2021 Late-breaking News

Genetic Testing | November 22, 2021

Susan Cheng, M.D., MPH, director of the Institute for Research on Healthy Aging in the Department of Cardiology at Cedars-Sinai, moderated the Best Science in Cardiovascular Genetics and Genomics: Building Blocks to Better Outcomes, at the American Heart Association (AHA) 2021 meeting. She is an expert in cardiac genetic testing and said tailoring LDL-lowering drug therapy based on routine genetic tests is coming, but is still a few years off.

Find more AHA 2021 late-breaking studies and video

Pharmaceuticals | November 22, 2021

Susan Cheng, M.D., MPH, director of the Institute for Research on Healthy Aging in the Department of Cardiology at Cedars-Sinai and the Erika J. Glazer Chair in Women's Cardiovascular Health and Population Science, led a discussion at the American Heart Association (AHA) 2021 meeting on novel therapeutics for the lipid lowering treatments. 

She discusses bempedoic acid, inclisiran to reduce LDL-C, icosapent ethyl and the use of genetic testing to further reduce high low-density lipoprotein (LDL) in patients were statin therapy is not enough.

Cheng discusses more in the VIDEO: Use of Genetic Testing to Tailor Lipid Lowering Therapies.

Find more AHA 2021 late-breaking studies and video

 

Subscribe Now